Chickenpox Vaccine Market Size, Share, Trends And Forecast 2024 To 2033

The chickenpox vaccine market size has grown strongly in recent years. It will grow from $3.38 billion in 2023 to $3.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to vaccine development, regulatory approvals, disease incidence, vaccination policies, public health initiatives.

The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $4.64 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to public perception and trust, pandemic preparedness, research and development, emerging market demand, healthcare infrastructure development. Major trends in the forecast period include vaccine education campaigns, adverse event monitoring, vaccine pricing strategies, advanced innovation, use of AI.

Market Overview -
Chickenpox vaccines are biological preparations that stimulate the cell-mediated immune response and prepare it to fight future infections caused by viruses by triggering IgG-mediated production of antibodies against varicella-zoster-specific pathogens that enter the body. The varicella-zoster virus causes chickenpox, which is a highly contagious disease (VZV).

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

Surge In Chickenpox Cases Driving Growth In Vaccine Market
The rising prevalence of chickenpox disease is expected to propel the growth of the chickenpox vaccine market going forward. Chickenpox disease refers to a severe infectious disease caused by the varicella-zoster virus (VZV) that causes a fluid-filled rash with an itchy rash. Increased cases of chickenpox necessitate more varicella vaccine immunization, thus, increasing demand for chickenpox vaccines. For instance, in April 2021, according to a report published by the Centers for Disease Control and Prevention (CDC), a US-based international public health agency, in the USA, around 4 million people have chickenpox annually, and over 10, 500 of them end up in hospitals, and between 100 and 150 of them pass away. Therefore, the rising prevalence of chickenpox disease is driving the growth of the chickenpox vaccine market.

Competitive Landscape -
Major companies operating in the chickenpox vaccine market report are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi Pasteur, AstraZeneca plc., GlaxoSmithKline plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Zydus Lifesciences Limited, Green Cross Corporation, Sinovac Biotech Ltd., GC Biopharma Corp., Emergent BioSolutions Inc., Bharat Biotech, Novo Medi Sciences Pvt. Ltd., Hualan Biological Engineering Inc., Chongqing Zhifei Biological Products Co. Ltd., Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Valneva SE, Serum Institute of India, Shenzhen Kangtai Biological Products Co. Ltd., SK Bioscience Co.Ltd., Biological E. Limited, PanGen Biotech Inc., Bio-Med, Parc-vaccinogène en Instituut Pasteur, Lucky Chemical Industrial Corporation, Biocad India Private Limited, Virchow Biotech Pvt. Ltd.

Innovative Drug Developments Transform Chickenpox Vaccine Landscape
Novel drug developments are the key trend gaining popularity in the chickenpox vaccine market. Major companies operating in the market are developing novel drugs with improved efficacy, innovative derivatives, and others to sustain their position in the market. For instance, in November 2022, Sinovac Biotech Ltd., a China-based company focused on research, development, and manufacturing of vaccines, stated that the World Health Organization (WHO) granted it prequalification for its live attenuated chickenpox (varicella) vaccine, which is the world's first varicella vaccine to receive prequalification. The Oka strain is the source of the varicella vaccine, which is produced in the exclusive Human Diploid Cell (SV-1 strain) of SINOVAC. This cell is created by cultivating and harvesting the virus, adding stabilizers, and freeze-drying it. A phase III efficacy trial found that the seroconversion rate of the vaccine-embedded children group, aged 1 to 12 years old, was 97.1%; the vaccine's efficacy against varicella and against breakthrough varicella was 87.1% and 89.2%, respectively. The vaccine offers 100 percent defense against mild and serious conditions.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Key Segments -

The chickenpox vaccine market covered in this report is segmented -

1) By Vaccine: Monovalent varicella vaccine, Combination varicella vaccine
2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination
3) By End-Users: Hospitals, Clinics, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.